APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Medicines for Alzheimer Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Medicines for Alzheimer Disease Treatment Market Outlook and Growth Opportunities 2026

Report ID 174011540430 December 2025194 pages

Choose your research edition.

Industry ResearchMedicines for Alzheimer Disease Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Medicines for Alzheimer Disease Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Medicines for Alzheimer Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Medicines for Alzheimer Disease Treatment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Medicines for Alzheimer Disease Treatment Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Medicines for Alzheimer Disease Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Medicines for Alzheimer Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Medicines for Alzheimer Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Medicines for Alzheimer Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Medicines for Alzheimer Disease Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Medicines for Alzheimer Disease Treatment market include Novartis AG, AbbVie Inc, Lupin Pharmaceuticals, Inc, Janssen Global Services, LLC, H. Lundbeck A/S, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company Limited, Amneal Pharmaceuticals LLC and Actiza Pharmaceutical Private Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Medicines for Alzheimer Disease Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Medicines for Alzheimer Disease Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Medicines for Alzheimer Disease Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Medicines for Alzheimer Disease Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Medicines for Alzheimer Disease Treatment Segment by Company

Novartis AG

AbbVie Inc

Lupin Pharmaceuticals, Inc

Janssen Global Services, LLC

H. Lundbeck A/S

F. Hoffmann-La Roche Ltd

Daiichi Sankyo Company Limited

Amneal Pharmaceuticals LLC

Actiza Pharmaceutical Private Limited

AC Immune

Medicines for Alzheimer Disease Treatment Segment by Type

NMDA Receptor Antagonists

Cholinesterase Inhibitors

Medicines for Alzheimer Disease Treatment Segment by Application

Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

Medicines for Alzheimer Disease Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Medicines for Alzheimer Disease Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Medicines for Alzheimer Disease Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Medicines for Alzheimer Disease Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Medicines for Alzheimer Disease Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medicines for Alzheimer Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Medicines for Alzheimer Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medicines for Alzheimer Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Medicines for Alzheimer Disease Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Medicines for Alzheimer Disease Treatment industry.

Chapter 3: Detailed analysis of Medicines for Alzheimer Disease Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Medicines for Alzheimer Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Medicines for Alzheimer Disease Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Medicines for Alzheimer Disease Treatment Industry Trends Table 2. Medicines for Alzheimer Disease Treatment Industry Drivers Table 3. Medicines for Alzheimer Disease Treatment Industry Opportunities and Challenges Table 4. Medicines for Alzheimer Disease Treatment Industry Restraints Table 5. Global Medicines for Alzheimer Disease Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Medicines for Alzheimer Disease Treatment Revenue Share by Company (2021-2026) Table 7. Global Medicines for Alzheimer Disease Treatment Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Medicines for Alzheimer Disease Treatment Sales Volume Share by Company (2021-2026) Table 9. Global Medicines for Alzheimer Disease Treatment Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Medicines for Alzheimer Disease Treatment Company Ranking, (2024-2026) & (USD Million) Table 11. Global Medicines for Alzheimer Disease Treatment Key Company Manufacturing Base & Headquarters Table 12. Global Medicines for Alzheimer Disease Treatment Company, Product Type & Application Table 13. Global Medicines for Alzheimer Disease Treatment Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Medicines for Alzheimer Disease Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of NMDA Receptor Antagonists Table 18. Significant Companies of Cholinesterase Inhibitors Table 19. Global Medicines for Alzheimer Disease Treatment Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 20. Global Medicines for Alzheimer Disease Treatment Sales Volume by Type (2021-2026) & (Tons) Table 21. Global Medicines for Alzheimer Disease Treatment Sales Volume by Type (2027-2032) & (Tons) Table 22. Global Medicines for Alzheimer Disease Treatment Sales Volume Share by Type (2021-2026) Table 23. Global Medicines for Alzheimer Disease Treatment Sales Volume Share by Type (2027-2032) Table 24. Global Medicines for Alzheimer Disease Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Medicines for Alzheimer Disease Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Medicines for Alzheimer Disease Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Medicines for Alzheimer Disease Treatment Sales Value Share by Type (2021-2026) Table 28. Global Medicines for Alzheimer Disease Treatment Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Pharmacy Table 30. Significant Companies of Online Pharmacy Table 31. Significant Companies of Retail Pharmacy Table 32. Global Medicines for Alzheimer Disease Treatment Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 33. Global Medicines for Alzheimer Disease Treatment Sales Volume by Application (2021-2026) & (Tons) Table 34. Global Medicines for Alzheimer Disease Treatment Sales Volume by Application (2027-2032) & (Tons) Table 35. Global Medicines for Alzheimer Disease Treatment Sales Volume Share by Application (2021-2026) Table 36. Global Medicines for Alzheimer Disease Treatment Sales Volume Share by Application (2027-2032) Table 37. Global Medicines for Alzheimer Disease Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Medicines for Alzheimer Disease Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Medicines for Alzheimer Disease Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Medicines for Alzheimer Disease Treatment Sales Value Share by Application (2021-2026) Table 41. Global Medicines for Alzheimer Disease Treatment Sales Value Share by Application (2027-2032) Table 42. Global Medicines for Alzheimer Disease Treatment Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 43. Global Medicines for Alzheimer Disease Treatment Sales by Region (2021-2026) & (Tons) Table 44. Global Medicines for Alzheimer Disease Treatment Sales Market Share by Region (2021-2026) Table 45. Global Medicines for Alzheimer Disease Treatment Sales by Region (2027-2032) & (Tons) Table 46. Global Medicines for Alzheimer Disease Treatment Sales Market Share by Region (2027-2032) Table 47. Global Medicines for Alzheimer Disease Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Medicines for Alzheimer Disease Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Medicines for Alzheimer Disease Treatment Sales Value Share by Region (2021-2026) Table 50. Global Medicines for Alzheimer Disease Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Medicines for Alzheimer Disease Treatment Sales Value Share by Region (2027-2032) Table 52. Global Medicines for Alzheimer Disease Treatment Market Average Price (US$/Ton) by Region (2021-2026) Table 53. Global Medicines for Alzheimer Disease Treatment Market Average Price (US$/Ton) by Region (2027-2032) Table 54. Global Medicines for Alzheimer Disease Treatment Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 55. Global Medicines for Alzheimer Disease Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Medicines for Alzheimer Disease Treatment Sales by Country (2021-2026) & (Tons) Table 57. Global Medicines for Alzheimer Disease Treatment Sales Market Share by Country (2021-2026) Table 58. Global Medicines for Alzheimer Disease Treatment Sales by Country (2027-2032) & (Tons) Table 59. Global Medicines for Alzheimer Disease Treatment Sales Market Share by Country (2027-2032) Table 60. Global Medicines for Alzheimer Disease Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Medicines for Alzheimer Disease Treatment Sales Value Market Share by Country (2021-2026) Table 62. Global Medicines for Alzheimer Disease Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Medicines for Alzheimer Disease Treatment Sales Value Market Share by Country (2027-2032) Table 64. Novartis AG Company Information Table 65. Novartis AG Business Overview Table 66. Novartis AG Medicines for Alzheimer Disease Treatment Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 67. Novartis AG Medicines for Alzheimer Disease Treatment Product Portfolio Table 68. Novartis AG Recent Development Table 69. AbbVie Inc Company Information Table 70. AbbVie Inc Business Overview Table 71. AbbVie Inc Medicines for Alzheimer Disease Treatment Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 72. AbbVie Inc Medicines for Alzheimer Disease Treatment Product Portfolio Table 73. AbbVie Inc Recent Development Table 74. Lupin Pharmaceuticals, Inc Company Information Table 75. Lupin Pharmaceuticals, Inc Business Overview Table 76. Lupin Pharmaceuticals, Inc Medicines for Alzheimer Disease Treatment Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 77. Lupin Pharmaceuticals, Inc Medicines for Alzheimer Disease Treatment Product Portfolio Table 78. Lupin Pharmaceuticals, Inc Recent Development Table 79. Janssen Global Services, LLC Company Information Table 80. Janssen Global Services, LLC Business Overview Table 81. Janssen Global Services, LLC Medicines for Alzheimer Disease Treatment Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 82. Janssen Global Services, LLC Medicines for Alzheimer Disease Treatment Product Portfolio Table 83. Janssen Global Services, LLC Recent Development Table 84. H. Lundbeck A/S Company Information Table 85. H. Lundbeck A/S Business Overview Table 86. H. Lundbeck A/S Medicines for Alzheimer Disease Treatment Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 87. H. Lundbeck A/S Medicines for Alzheimer Disease Treatment Product Portfolio Table 88. H. Lundbeck A/S Recent Development Table 89. F. Hoffmann-La Roche Ltd Company Information Table 90. F. Hoffmann-La Roche Ltd Business Overview Table 91. F. Hoffmann-La Roche Ltd Medicines for Alzheimer Disease Treatment Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 92. F. Hoffmann-La Roche Ltd Medicines for Alzheimer Disease Treatment Product Portfolio Table 93. F. Hoffmann-La Roche Ltd Recent Development Table 94. Daiichi Sankyo Company Limited Company Information Table 95. Daiichi Sankyo Company Limited Business Overview Table 96. Daiichi Sankyo Company Limited Medicines for Alzheimer Disease Treatment Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 97. Daiichi Sankyo Company Limited Medicines for Alzheimer Disease Treatment Product Portfolio Table 98. Daiichi Sankyo Company Limited Recent Development Table 99. Amneal Pharmaceuticals LLC Company Information Table 100. Amneal Pharmaceuticals LLC Business Overview Table 101. Amneal Pharmaceuticals LLC Medicines for Alzheimer Disease Treatment Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 102. Amneal Pharmaceuticals LLC Medicines for Alzheimer Disease Treatment Product Portfolio Table 103. Amneal Pharmaceuticals LLC Recent Development Table 104. Actiza Pharmaceutical Private Limited Company Information Table 105. Actiza Pharmaceutical Private Limited Business Overview Table 106. Actiza Pharmaceutical Private Limited Medicines for Alzheimer Disease Treatment Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 107. Actiza Pharmaceutical Private Limited Medicines for Alzheimer Disease Treatment Product Portfolio Table 108. Actiza Pharmaceutical Private Limited Recent Development Table 109. AC Immune Company Information Table 110. AC Immune Business Overview Table 111. AC Immune Medicines for Alzheimer Disease Treatment Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 112. AC Immune Medicines for Alzheimer Disease Treatment Product Portfolio Table 113. AC Immune Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Medicines for Alzheimer Disease Treatment Distributors List Table 117. Medicines for Alzheimer Disease Treatment Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Medicines for Alzheimer Disease Treatment Product Image Figure 2. Global Medicines for Alzheimer Disease Treatment Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Medicines for Alzheimer Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 4. Global Medicines for Alzheimer Disease Treatment Sales (2021-2032) & (Tons) Figure 5. Global Medicines for Alzheimer Disease Treatment Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Medicines for Alzheimer Disease Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. NMDA Receptor Antagonists Image Figure 10. Cholinesterase Inhibitors Image Figure 11. Global Medicines for Alzheimer Disease Treatment Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 12. Global Medicines for Alzheimer Disease Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Medicines for Alzheimer Disease Treatment Sales Volume Share by Type (2021-2032) Figure 14. Global Medicines for Alzheimer Disease Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Medicines for Alzheimer Disease Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Medicines for Alzheimer Disease Treatment Sales Value Share by Type (2021-2032) Figure 17. Hospital Pharmacy Image Figure 18. Online Pharmacy Image Figure 19. Retail Pharmacy Image Figure 20. Global Medicines for Alzheimer Disease Treatment Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 21. Global Medicines for Alzheimer Disease Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Medicines for Alzheimer Disease Treatment Sales Volume Share by Application (2021-2032) Figure 23. Global Medicines for Alzheimer Disease Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Medicines for Alzheimer Disease Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Medicines for Alzheimer Disease Treatment Sales Value Share by Application (2021-2032) Figure 26. Global Medicines for Alzheimer Disease Treatment Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 27. Global Medicines for Alzheimer Disease Treatment Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Medicines for Alzheimer Disease Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Medicines for Alzheimer Disease Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Medicines for Alzheimer Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 31. North America Medicines for Alzheimer Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Medicines for Alzheimer Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Medicines for Alzheimer Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Medicines for Alzheimer Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Medicines for Alzheimer Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Medicines for Alzheimer Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 37. South America Medicines for Alzheimer Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Medicines for Alzheimer Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Medicines for Alzheimer Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Medicines for Alzheimer Disease Treatment Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Medicines for Alzheimer Disease Treatment Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • NMDA Receptor Antagonists
  • Cholinesterase Inhibitors
Applications
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
Companies covered
  • Novartis AG
  • AbbVie Inc
  • Lupin Pharmaceuticals, Inc
  • Janssen Global Services, LLC
  • H. Lundbeck A/S
  • F. Hoffmann-La Roche Ltd
  • Daiichi Sankyo Company Limited
  • Amneal Pharmaceuticals LLC
  • Actiza Pharmaceutical Private Limited
  • AC Immune

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Medicines for Alzheimer Disease Treatment Sales Value (2021-2032)
  4. 1.2.2 Global Medicines for Alzheimer Disease Treatment Sales Volume (2021-2032)
  5. 1.2.3 Global Medicines for Alzheimer Disease Treatment Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Medicines for Alzheimer Disease Treatment Market Dynamics
  1. 2.1 Medicines for Alzheimer Disease Treatment Industry Trends
  2. 2.2 Medicines for Alzheimer Disease Treatment Industry Drivers
  3. 2.3 Medicines for Alzheimer Disease Treatment Industry Opportunities and Challenges
  4. 2.4 Medicines for Alzheimer Disease Treatment Industry Restraints
3 Medicines for Alzheimer Disease Treatment Market by Company
  1. 3.1 Global Medicines for Alzheimer Disease Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Medicines for Alzheimer Disease Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Medicines for Alzheimer Disease Treatment Sales Volume by Company (2021-2026)
  4. 3.4 Global Medicines for Alzheimer Disease Treatment Average Price by Company (2021-2026)
  5. 3.5 Global Medicines for Alzheimer Disease Treatment Company Ranking (2024-2026)
  6. 3.6 Global Medicines for Alzheimer Disease Treatment Company Manufacturing Base and Headquarters
  7. 3.7 Global Medicines for Alzheimer Disease Treatment Company Product Type and Application
  8. 3.8 Global Medicines for Alzheimer Disease Treatment Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Medicines for Alzheimer Disease Treatment Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Medicines for Alzheimer Disease Treatment Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Medicines for Alzheimer Disease Treatment Market by Type
  1. 4.1 Medicines for Alzheimer Disease Treatment Type Introduction
  2. 4.1.1 NMDA Receptor Antagonists
  3. 4.1.2 Cholinesterase Inhibitors
  4. 4.2 Global Medicines for Alzheimer Disease Treatment Sales Volume by Type
  5. 4.2.1 Global Medicines for Alzheimer Disease Treatment Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Medicines for Alzheimer Disease Treatment Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Medicines for Alzheimer Disease Treatment Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Medicines for Alzheimer Disease Treatment Sales Value by Type
  9. 4.3.1 Global Medicines for Alzheimer Disease Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Medicines for Alzheimer Disease Treatment Sales Value by Type (2021-2032)
  11. 4.3.3 Global Medicines for Alzheimer Disease Treatment Sales Value Share by Type (2021-2032)
5 Medicines for Alzheimer Disease Treatment Market by Application
  1. 5.1 Medicines for Alzheimer Disease Treatment Application Introduction
  2. 5.1.1 Hospital Pharmacy
  3. 5.1.2 Online Pharmacy
  4. 5.1.3 Retail Pharmacy
  5. 5.2 Global Medicines for Alzheimer Disease Treatment Sales Volume by Application
  6. 5.2.1 Global Medicines for Alzheimer Disease Treatment Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Medicines for Alzheimer Disease Treatment Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Medicines for Alzheimer Disease Treatment Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Medicines for Alzheimer Disease Treatment Sales Value by Application
  10. 5.3.1 Global Medicines for Alzheimer Disease Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Medicines for Alzheimer Disease Treatment Sales Value by Application (2021-2032)
  12. 5.3.3 Global Medicines for Alzheimer Disease Treatment Sales Value Share by Application (2021-2032)
6 Medicines for Alzheimer Disease Treatment Regional Sales and Value Analysis
  1. 6.1 Global Medicines for Alzheimer Disease Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Medicines for Alzheimer Disease Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Medicines for Alzheimer Disease Treatment Sales by Region: 2021-2026
  4. 6.2.2 Global Medicines for Alzheimer Disease Treatment Sales by Region (2027-2032)
  5. 6.3 Global Medicines for Alzheimer Disease Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Medicines for Alzheimer Disease Treatment Sales Value by Region (2021-2032)
  7. 6.4.1 Global Medicines for Alzheimer Disease Treatment Sales Value by Region: 2021-2026
  8. 6.4.2 Global Medicines for Alzheimer Disease Treatment Sales Value by Region (2027-2032)
  9. 6.5 Global Medicines for Alzheimer Disease Treatment Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Medicines for Alzheimer Disease Treatment Sales Value (2021-2032)
  12. 6.6.2 North America Medicines for Alzheimer Disease Treatment Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Medicines for Alzheimer Disease Treatment Sales Value (2021-2032)
  15. 6.7.2 Europe Medicines for Alzheimer Disease Treatment Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Medicines for Alzheimer Disease Treatment Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Medicines for Alzheimer Disease Treatment Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Medicines for Alzheimer Disease Treatment Sales Value (2021-2032)
  21. 6.9.2 South America Medicines for Alzheimer Disease Treatment Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Medicines for Alzheimer Disease Treatment Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Medicines for Alzheimer Disease Treatment Sales Value Share by Country, 2025 VS 2032
7 Medicines for Alzheimer Disease Treatment Country-level Sales and Value Analysis
  1. 7.1 Global Medicines for Alzheimer Disease Treatment Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Medicines for Alzheimer Disease Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Medicines for Alzheimer Disease Treatment Sales by Country (2021-2032)
  4. 7.3.1 Global Medicines for Alzheimer Disease Treatment Sales by Country (2021-2026)
  5. 7.3.2 Global Medicines for Alzheimer Disease Treatment Sales by Country (2027-2032)
  6. 7.4 Global Medicines for Alzheimer Disease Treatment Sales Value by Country (2021-2032)
  7. 7.4.1 Global Medicines for Alzheimer Disease Treatment Sales Value by Country (2021-2026)
  8. 7.4.2 Global Medicines for Alzheimer Disease Treatment Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Medicines for Alzheimer Disease Treatment Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Medicines for Alzheimer Disease Treatment Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Medicines for Alzheimer Disease Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Medicines for Alzheimer Disease Treatment Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Medicines for Alzheimer Disease Treatment Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 AbbVie Inc
  8. 8.2.1 AbbVie Inc Company Information
  9. 8.2.2 AbbVie Inc Business Overview
  10. 8.2.3 AbbVie Inc Medicines for Alzheimer Disease Treatment Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AbbVie Inc Medicines for Alzheimer Disease Treatment Product Portfolio
  12. 8.2.5 AbbVie Inc Recent Developments
  13. 8.3 Lupin Pharmaceuticals, Inc
  14. 8.3.1 Lupin Pharmaceuticals, Inc Company Information
  15. 8.3.2 Lupin Pharmaceuticals, Inc Business Overview
  16. 8.3.3 Lupin Pharmaceuticals, Inc Medicines for Alzheimer Disease Treatment Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Lupin Pharmaceuticals, Inc Medicines for Alzheimer Disease Treatment Product Portfolio
  18. 8.3.5 Lupin Pharmaceuticals, Inc Recent Developments
  19. 8.4 Janssen Global Services, LLC
  20. 8.4.1 Janssen Global Services, LLC Company Information
  21. 8.4.2 Janssen Global Services, LLC Business Overview
  22. 8.4.3 Janssen Global Services, LLC Medicines for Alzheimer Disease Treatment Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Janssen Global Services, LLC Medicines for Alzheimer Disease Treatment Product Portfolio
  24. 8.4.5 Janssen Global Services, LLC Recent Developments
  25. 8.5 H. Lundbeck A/S
  26. 8.5.1 H. Lundbeck A/S Company Information
  27. 8.5.2 H. Lundbeck A/S Business Overview
  28. 8.5.3 H. Lundbeck A/S Medicines for Alzheimer Disease Treatment Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 H. Lundbeck A/S Medicines for Alzheimer Disease Treatment Product Portfolio
  30. 8.5.5 H. Lundbeck A/S Recent Developments
  31. 8.6 F. Hoffmann-La Roche Ltd
  32. 8.6.1 F. Hoffmann-La Roche Ltd Company Information
  33. 8.6.2 F. Hoffmann-La Roche Ltd Business Overview
  34. 8.6.3 F. Hoffmann-La Roche Ltd Medicines for Alzheimer Disease Treatment Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 F. Hoffmann-La Roche Ltd Medicines for Alzheimer Disease Treatment Product Portfolio
  36. 8.6.5 F. Hoffmann-La Roche Ltd Recent Developments
  37. 8.7 Daiichi Sankyo Company Limited
  38. 8.7.1 Daiichi Sankyo Company Limited Company Information
  39. 8.7.2 Daiichi Sankyo Company Limited Business Overview
  40. 8.7.3 Daiichi Sankyo Company Limited Medicines for Alzheimer Disease Treatment Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Daiichi Sankyo Company Limited Medicines for Alzheimer Disease Treatment Product Portfolio
  42. 8.7.5 Daiichi Sankyo Company Limited Recent Developments
  43. 8.8 Amneal Pharmaceuticals LLC
  44. 8.8.1 Amneal Pharmaceuticals LLC Company Information
  45. 8.8.2 Amneal Pharmaceuticals LLC Business Overview
  46. 8.8.3 Amneal Pharmaceuticals LLC Medicines for Alzheimer Disease Treatment Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Amneal Pharmaceuticals LLC Medicines for Alzheimer Disease Treatment Product Portfolio
  48. 8.8.5 Amneal Pharmaceuticals LLC Recent Developments
  49. 8.9 Actiza Pharmaceutical Private Limited
  50. 8.9.1 Actiza Pharmaceutical Private Limited Company Information
  51. 8.9.2 Actiza Pharmaceutical Private Limited Business Overview
  52. 8.9.3 Actiza Pharmaceutical Private Limited Medicines for Alzheimer Disease Treatment Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Actiza Pharmaceutical Private Limited Medicines for Alzheimer Disease Treatment Product Portfolio
  54. 8.9.5 Actiza Pharmaceutical Private Limited Recent Developments
  55. 8.10 AC Immune
  56. 8.10.1 AC Immune Company Information
  57. 8.10.2 AC Immune Business Overview
  58. 8.10.3 AC Immune Medicines for Alzheimer Disease Treatment Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 AC Immune Medicines for Alzheimer Disease Treatment Product Portfolio
  60. 8.10.5 AC Immune Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Medicines for Alzheimer Disease Treatment Value Chain Analysis
  2. 9.1.1 Medicines for Alzheimer Disease Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Medicines for Alzheimer Disease Treatment Sales Mode & Process
  6. 9.2 Medicines for Alzheimer Disease Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Medicines for Alzheimer Disease Treatment Distributors
  9. 9.2.3 Medicines for Alzheimer Disease Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst